Brief: Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
20/05/2025 13:16
May 20 (Reuters) - Neuraxis Inc NRXS.A: NEURAXIS AWARDED FIRST EVER FDA CLEARANCE FOR THE TREATMENT OF PEDIATRIC FAP/FUNCTIONAL DYSPEPSIA (FD) AND ASSOCIATED NAUSEA SYMPTOMS NEURAXIS INC: CLEARANCE COVERS PATIENTS AGED 8-21 NEURAXIS INC - COMMERCIAL ROLLOUT FOR NEW INDICATION BEGINS IMMEDIATELY Source text: ID:nGNX5pxStk Further company coverage: NRXS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuraxis
See all newsBrief: Neuraxis Inc Expects Net Sales Of About $1.6 Million For Three Months Ended March 31, 2026
Brief: Neuraxis Reports Strong Fourth Quarter And Full Year 2025 Financial Results
Brief: Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access To More Patients With Functional Abdominal Pain
Brief: Neuraxis Wins First FDA Nod for FD Pain Treatment
Brief: Neuraxis Terminates License Agreement With Masimo